Murakami R, et al. - Whether the optimal treatment of the various histopathological subtypes of high-grade serous ovarian cancer [(HGSOC), that includes mesenchymal transition (MT) type, the immune reactive type, the solid and proliferative type and the papillo-glandular type] needs individualized chemotherapy was investigated in this study. For each histopathological subtype, progression-free survival (PFS) was compared between the paclitaxel and carboplatin (TC) group and the dose-dense TC (ddTC) group. Findings revealed that these subtypes had different PFS as well as overall survival (OS). The shortest PFS (median 1.4 y) and OS (median 3.6 y) was seen in the MT subtype. The ddTC group vs the TC group experienced a longer PFS, median 1.8 y and median 1.2 y, respectively, in the MT subtype. Sensitivity to taxane was reported for the MT type of HGSOC and thus, the ddTC regimen was advised for this histopathological subtype.